pancreatic tumor
These findings imply that assessing the COX-2 profile of the pancreatic tumor is mandatory before initiating therapy with a selective COX-2 inhibitor.
These findings imply that assessing the <span class="gene" id="15705899-14-40-45">COX-2</span> profile of the <span class="disease" id="15705899-14-61-77">pancreatic tumor</span> is mandatory before initiating therapy with a selective <span class="gene" id="15705899-14-134-139">COX-2</span> inhibitor.